Actively Recruiting
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
Led by Washington University School of Medicine · Updated on 2025-09-23
40
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The use of glucagon-like peptide receptor agonists (GLP-1 RAs) may have clinically important effects on skeletal muscle mass (SMM), and physical function. The effects of exercise training in conjunction with GLP-1 RA therapy on these outcomes has not been studied. Additionally, most people treated with GLP-1-based weight loss medications stop taking these medications within 1 year of initiating treatment. This is an important clinical concern because weight regain can occur after weight loss pharmacotherapy is stopped and the impact of stopping GLP-1 RA therapy on physical and metabolic function has not been studied. In this study, the investigators will conduct a 2-year randomized clinical trial to evaluate body composition, muscle physical and metabolic function, and muscle strength in response to GLP-1 RA therapy, with or without exercise training, and subsequent treatment cessation on muscle-related outcomes.
CONDITIONS
Official Title
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Obesity (Body Mass Index 30 kg/m2 or higher)
- Decreased physical function with a Modified Physical Performance Test score between 17 and 31
- Approval from primary physician to participate in the study
You will not qualify if you...
- Unstable weight with more than 4% change in the last 2 months before the study
- Engaging in 150 minutes or more per week of structured exercise
- Diagnosis of diabetes
- Significant heart or lung diseases, uncontrolled high blood pressure, or other organ dysfunction (e.g., severe kidney problems)
- Current use of GLP-1 or other weight loss medications
- Serious stomach emptying problems or regular use of drugs affecting gastrointestinal movement
- History of chronic or acute pancreatitis
- Thyroid-stimulating hormone (TSH) greater than 1.5 times the upper limit of normal unless stable thyroid treatment for at least 3 months
- Recent severe or unstable major depressive disorder or other serious psychiatric illness within 2 months
- Acute or chronic hepatitis or other liver diseases except Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Active or untreated cancer or remission less than 5 years for significant cancers (excluding certain skin and in situ cancers)
- Tobacco use, excessive alcohol intake, active substance abuse, or recent marijuana use without willingness to abstain during the trial
- Use of medications that affect study measures or pose risk and cannot be stopped temporarily
- Previous or planned bariatric or endoscopic obesity surgery
- Anemia with hemoglobin less than 10 g/dL
- Conditions preventing completion of all testing procedures (e.g., severe mobility issues, limb amputations, metal implants interfering with imaging, coagulation disorders)
- History of seizure disorder
- Female who is pregnant, breastfeeding, or plans to become pregnant
- Allergy or hypersensitivity to GLP-1 receptor agonist medications
- Unable to provide informed consent
- Unable or unwilling to follow study protocol or deemed unsuitable by research team
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
C
Coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here